Inventiva to present three lanifibranor abstracts at AASLD Liver Meeting 2026

Inventiva said on October 6, 2026 that it will present three scientific abstracts at the AASLD The Liver Meeting 2026, to be held from November 5-9, 2026, in Denver, Colorado.¹

The abstracts cover preclinical and clinical findings on lanifibranor's mechanism as a pan-PPAR agonist. One poster, titled "Lanifibranor Targets Multiple Hepatic Cell Populations to Reduce Fibrosis Through Balanced Pan-PPAR Activation," will be presented on November 7, 2026 by Guillaume Wettstein and co-authors. A second poster, "Lanifibranor Improved Liver Sinusoidal Endothelial Cell Dysfunction and Vascular Alterations Across All Stages From MASH To Cirrhosis," is also scheduled for November 7, 2026. A third, on methylation patterns across PPAR isoforms in plasma cell-free DNA in MASLD patients, is set for November 5, 2026.

The company said the abstracts provide further characterization of the biological rationale for the balanced pan-PPAR approach of lanifibranor, highlighting complementary activities observed across multiple hepatic cell populations and pathways implicated in MASH pathophysiology.¹

Separately, Inventiva noted that lanifibranor is currently being evaluated in the Phase 3 NATiV3 clinical trial for the treatment of patients with MASH with moderate and advanced fibrosis¹, with the company stating that topline results from that trial are expected in the fourth quarter of 2026.

Inventiva described lanifibranor as an orally available small molecule that activates all three peroxisome proliferator-activated receptor isoforms, with a well-balanced activation of PPARα and PPARδ and a partial activation of PPARγ.¹ The FDA has granted the drug Breakthrough Therapy and Fast Track designation for the treatment of MASH.¹ Lanifibranor is an investigational medicine that has not been approved by any regulatory authority, and its safety and efficacy have not been established.¹